Terms: = Kidney tumors AND MYC, c-Myc, 4609, ENSG00000136997 AND Clinical Outcome
5 results:
1. Elevated SNRPA1, as a Promising Predictor Reflecting Severe clinical outcome
Jiang A; Meng J; Gong W; Zhang Z; Gan X; Wang J; Wu Z; Liu B; Qu L; Wang L
Front Immunol; 2022; 13():842069. PubMed ID: 35281041
[TBL] [Abstract] [Full Text] [Related]
2. Molecular characterisation of metanephric adenomas beyond BRAF: genetic evidence for potential malignant evolution.
Chan E; Stohr BA; Croom NA; Cho SJ; Garg K; Troxell ML; Higgins JP; Bean GR
Histopathology; 2020 Jun; 76(7):1084-1090. PubMed ID: 32064677
[TBL] [Abstract] [Full Text] [Related]
3. A pan-cancer analysis of myc-PVT1 reveals CNV-unmediated deregulation and poor prognosis in renal carcinoma.
Posa I; Carvalho S; Tavares J; Grosso AR
Oncotarget; 2016 Jul; 7(30):47033-47041. PubMed ID: 27366943
[TBL] [Abstract] [Full Text] [Related]
4. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis.
Monzon FA; Alvarez K; Peterson L; Truong L; Amato RJ; Hernandez-McClain J; Tannir N; Parwani AV; Jonasch E
Mod Pathol; 2011 Nov; 24(11):1470-9. PubMed ID: 21725288
[TBL] [Abstract] [Full Text] [Related]
5. L-myc allelotype in renal cell carcinoma.
Presti JC; Hinckley J; Reuter VE
Cancer Genet Cytogenet; 1996 May; 88(1):66-8. PubMed ID: 8630982
[TBL] [Abstract] [Full Text] [Related]
